200,000+ products from a single source!
sales@angenechem.com
Home > Pyridines > 161417-03-4
161417-03-4 | Pyridine, 2-methyl-3-[(2S)-2-pyrrolidinylmethoxy]-
CAS No: 161417-03-4 Catalog No: AG001SGG MDL No:MFCD11974724
Product Description
Catalog Number:
AG001SGG
Chemical Name:
Pyridine, 2-methyl-3-[(2S)-2-pyrrolidinylmethoxy]-
CAS Number:
161417-03-4
Molecular Formula:
C11H16N2O
Molecular Weight:
192.2575
MDL Number:
MFCD11974724
IUPAC Name:
2-methyl-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine
InChI:
InChI=1S/C11H16N2O/c1-9-11(5-3-6-12-9)14-8-10-4-2-7-13-10/h3,5-6,10,13H,2,4,7-8H2,1H3/t10-/m0/s1
InChI Key:
YRVIKLBSVVNSHF-JTQLQIEISA-N
SMILES:
Cc1ncccc1OC[C@@H]1CCCN1
UNII:
CL2002R563
Properties
Complexity:
175
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
192.126g/mol
Formal Charge:
0
Heavy Atom Count:
14
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
192.262g/mol
Monoisotopic Mass:
192.126g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
34.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.3
Literature
| Title | Journal |
|---|---|
| A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. | The Journal of clinical psychiatry 20120601 |
| [Stimulant and non-stimulant medication in current and future therapy for ADHD]. | Fortschritte der Neurologie-Psychiatrie 20120301 |
| Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. | Psychopharmacology 20120201 |
| Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as potent α4β2 nicotinic acetylcholine receptor ligands. | Journal of medicinal chemistry 20111110 |
| Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089. | The Journal of pharmacology and experimental therapeutics 20110301 |
| Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. | Journal of the American Academy of Child and Adolescent Psychiatry 20110101 |
| Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. | Biochemical pharmacology 20091001 |
| Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20080402 |
| Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. | Biochemical pharmacology 20071015 |
| ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. | Biological psychiatry 20060601 |
| ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. | CNS drug reviews 20040101 |
| 2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization. | Journal of medicinal chemistry 20011220 |
| Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. | European journal of pharmacology 19990205 |
| Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. | Psychopharmacology 19980301 |
| ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. | The Journal of pharmacology and experimental therapeutics 19971001 |
| ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. | The Journal of pharmacology and experimental therapeutics 19971001 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.